About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, November 6th, 2012

The QualityStocks
Daily Stock List

graphic
graphic

Petro Vista Energy Corp. (PTV.V)

Today we are reporting on Petro Vista Energy Corp. (PTV.V), here at the QualityStocks Daily Newsletter.

Headquartered in Vancouver, British Columbia, Petro Vista Energy Corp. is an oil and gas exploration company. The Company has near-term production opportunities in South America. Petro Vista Energy has exploration, development and production rights in Brazil. The Company's shares trade on the TSX Venture Exchange. In addition, Petro Vista has an office in Aracaju, Brazil.

The Company's corporate mission is to build an upstream oil and gas company with exploration and production focused in the highest resource potential and commercially attractive countries in South America. Petro Vista's plans for success include a balanced project strategy including production and high-impact upside potential; a technology partnership for geotechnical and operational excellence, and high-quality deal flows with experienced and well-connected management.

Petro Vista Energy has earned the right to acquire a 37.5 percent Working Interest (WI) (27.3 percent net revenue interest) in the shallow offshore and producing oil concession Block SES-107D (Tartaruga Block). The acquisition of the WI is subject to the receipt of all necessary approvals including the approval of the Agencia Nacional do Petroleo, Gas Natural e Biocombustiveis (ANP) to the assignment of the working interest. The Company is awaiting receipt of these approvals.  

The Tartaruga Block is located on Brazil's east coast adjacent to the large Miranga Oil Field (Petrobras) having over 814 MMBOE in place, and the Carmopolis Oil Field with over 528 MMBOE. The Tartaruga Block is in the Sergipe Alagoas Basin. In the Tartaruga field, the Operator is UP Petroleo Brasil Ltda.

Last week, Petro Vista Energy provided an operations update.  Concerning the Tartaruga Work-Over, the work-over program to install a downhole Electric Submersible Pump (ESP) on the 7- TTG well in the Tartaruga Field in Brazil by the Operator was successfully completed. The well was placed on production and produced 486 barrels of oil in the first 24 hours of operation.

The well is now being placed on production to determine the optimum level of long-term production rates. Petro Vista Energy will provide an update on production rates, as these are determined.

Petro Vista Energy Corp. (PTV.V), closed Tuesday's trading session at $0.035, even for the day, on 472,888 volume. The stock's 52-week low/high is $0.03/$0.12.

NeoMedia Technologies, Inc. (NEOM)

The Penny Mafia, Greenbackers, OTCPicks, and Jason Bond reported earlier on NeoMedia Technologies, Inc. (NEOM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Boulder, Colorado, NeoMedia Technologies, Inc. is the global market leader in 2D mobile barcode technology and infrastructure solutions that enable the mobile barcode ecosystem globally. Their technology platform transforms mobile devices with cameras into barcode scanners. This enables a range of practical and engaging applications such as consumer oriented advertising, mobile ticketing and couponing, and business-to-business (B2B) commercial track and trace solutions. NeoMedia Technologies' shares trade on the OTCQB.

NeoMedia's solutions have transformed close to 25 million mobile devices with cameras across 193 countries into the aforementioned barcode scanners. The Company offers customers a comprehensive end-to-end mobile code solution. Their current customers include handset manufacturers, platform providers, as well as brands and agencies looking to offer pioneering mobile barcode solutions to their customer base. NeoMedia's product portfolio includes mobile barcode management & infrastructure solutions, barcode reader solutions, mobile couponing, mobile ticketing & POS integration and IP licensing.

They offer their NeoReader® - a universal mobile barcode application. NeoReader is one of the leading barcode scanning applications currently available. It is presently installed on over 20 million devices and available for more than 700 mobile device types. When used in conjunction with the Company's barcode management system, NeoSphere, it delivers rich metadata to brands and marketers looking to better understand the who, what, when, where, and why of each scan their campaign receives. NeoReader is easy to download, and is available on all major app stores.

In September, NeoMedia Technologies announced two new patent licensees to their portfolio of barcode related patents. Paperlinks, Inc. and CodeBroker LLC are the two new licensees. Recently, NeoMedia announced that 4GQR LLC, a provider of QR code technology, is a new patent licensee to NeoMedia's portfolio of barcode related patents. 4GQR joins a growing list of companies actively licensed to use NeoMedia Technologies' patents, a list which includes industry-leading companies such as Microsoft.

NeoMedia Technologies, Inc. (NEOM), closed Tuesday's trading session at $0.0057, up 3.64%, on 11,213,947 volume with 103 trades. The average volume for the last 60 days is 25,475,901 and the stock's 52-week low/high is $0.0001/$0.0585.

CytoDyn, Inc. (CYDY)

AllPennyStocks reported recently on CytoDyn, Inc. (CYDY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CytoDyn, Inc. develops first-in-class biologic therapeutics to treat and prevent infectious diseases in humans. A biotechnology company, they focus on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Mr. Allen D. Allen, the Company founder, created Cytolin®, their trademarked HIV/AIDS products name. CytoDyn's shares trade on the OTCQB. The Company has their corporate headquarters in Lake Oswego, Oregon.

CytoDyn's proprietary drug candidate Cytolin® is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. The Company's intention is to explore the clinical development of Cytolin® for persons infected with the Human Immunodeficiency Virus (HIV) to determine if it could perturb the natural course of HIV infection. They recently completed a humanized antibody construct of Cytolin®, filed a provisional patent for its use, and manufacturing discussions are taking place.

Furthermore, CytoDyn is exploring the possible application of their existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus (FIV), a retroviral infection in cats. Recently, they filed for a provisional patent for the use of these antibodies and selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV.

In October, CytoDyn announced their purchase of PRO 140 from Progenics, Inc. PRO 140 is a humanized cell-specific monoclonal antibody. It is in development for the treatment of HIV that targets an essential co-receptor for HIV known as CCR5. PRO 140 is currently in late Stage II clinical development.

With the addition of PRO 140, CytoDyn now owns the two cell-specific monoclonal antibodies under development for the treatment of HIV, the other being the aforementioned Cytolin®. These two antibodies fall into an emerging new class of treatments known as entry inhibitors.

PRO 140 is currently the most advanced experimental monoclonal antibody for HIV treatment. It has been used in approximately 100 HIV-infected subjects in placebo controlled FDA-approved clinical trials. It has received designation as a Fast Track drug candidate by the FDA and has completed Phase IA and Phase IIA studies.

CytoDyn, Inc. (CYDY), closed Tuesday's trading session at $1.01, up 1.00%, on 100,712 volume with 24 trades. The average volume for the last 60 days is 55,666 and the stock's 52-week low/high is $0.62/$4.45.

ENGlobal Corp. (ENG)

UndiscoveredEquities reported this month on ENGlobal Corp. (ENG), Street Insider, AllPennyStocks, OTCPicks, Stockhouse, SmallCapVoice, Nebula Stocks, Vantage Wire did earlier, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

ENGlobal Corp. is a provider of engineering and related project services mainly to the energy sector throughout the United States and around the world. The Company operates by way of two business segments: Automation and Engineering & Construction. ENGlobal has approximately 1,500 employees in 12 offices and 9 cities. The Company lists on the NASDAQ Global Market. Founded in 1985, ENGlobal has their corporate headquarters in Houston, Texas.

The Company's Automation segment designs, assembles, programs, installs, integrates and services process control, analytical and heat tracing systems for specific applications in the energy and processing related industries. Additionally, the Automation segment provides fabrication and implementation of process distributed control and analyzer systems, advanced automation, and related information technology services.

The Engineering & Construction segment provides consulting services relating to the development, management and execution of projects requiring professional engineering as well as inspection, construction management, mechanical integrity, field support, quality assurance and plant asset management. The Engineering & Construction group offers development, management and turnkey execution of engineering projects in the upstream, midstream and downstream energy industries.

Markets served by ENGlobal include Petroleum Refining, Petrochemical, Chemical, Pipelines, Gas Processing, Utilities, Power & Co-generation, Renewable Energy, Manufacturing, and Telecommunications. In addition, markets include Oil & Gas Production, Governmental, Forest Products, Environmental, Land & Regulatory, and Offshore.

Today, ENGlobal announced that they successfully completed the divestiture of their Land and Right of Way division to Steele & Company, LP based in Tyler, Texas. With this final agreement, ENGlobal will retain approximately $4.5 million of this division's working capital at the time of closing, in addition to receiving a $3.0 million promissory note payable over four years from Steele. Subject to the agreement, the purchase price was adjusted based on the net working capital of the division at the time of closing. ENGlobal's intention is to use the net proceeds from this transaction to reduce outstanding debt.

ENGlobal Corp. (ENG), closed Tuesday's trading session at $0.40, down 4.74, on 60,135 volume with 102 trades. The average volume for the last 60 days is 106,299 and the stock's 52-week low/high is $0.315/$2.99.

Teryl Resources Corp. (TRYLF)

MonsterStocksPicks, Stock Stars, AllPennyStocks, BabyBulls, and Bull Ventures reported earlier on Teryl Resources Corp.(TRYLF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Teryl Resources Corp. is a junior precious metals exploration company with corporate headquarters in Richmond, British Columbia. The Company holds interests in Gold & Silver properties in Alaska and Northern British Columbia. Teryl has a number of gold prospects in Alaska near the Kinross Fort Knox Mine. The Company's shares trade on the OTCQB and on the TSX Venture Exchange (TRC.V).

In Alaska, Teryl Resources has a 10 percent net profit interest in the Stepovich claims. They also have a 100 percent interest in the Westridge property and a 50 percent option on the Fish Creek property, adjacent to the Gil property. The Company sold their 20 percent interest in the Gil property in Fairbanks, Alaska to Fairbanks Gold Mining Corp.

Teryl Resources owns a 30 percent Working Interest (WI) and a 10 percent NPI interest in the Silverknife property. Silverknife is a silver/lead/zinc prospect located in Northern British Columbia next to Silvercorp's silver/lead/zinc discovery. Teryl has a small revenue interest in three producing oil and gas wells in Texas with Anadarko Petroleum as the operator.

Early last month, Teryl Resources and Minewest Silver and Gold (a subsidiary of Reg Technologies) announced that the first phase of exploration on the silver, lead, zinc prospect in the Liard Mining District in British Columbia was completed. The exploration crew re-boxed the core from the diamond drilling completed in 1985 through 1987; 101 core samples were collected, split and/or quartered (where applicable) and submitted for chemical  analysis by Multielemt ICP. The critical high-grade silver/lead/zinc sections were re-logged and submitted for assays.

The Silverknife Property lies in a well-mineralized and historically and currently important precious and base metals exploration intensive region. The Property hosts a known historic prospect (the Silverknife Prospect) with defined Ag-Pb-Zn mineralization within only two km of Silvercorp's active Silvertip Ag-Pb-Zn deposit. The Property represents a prospective target for precious and base metals mineralization genetically related to the Silvertip deposit.

Teryl Resources Corp. (TRYLF), closed Tuesday's session at $0.0643, even for the day. The average volume for the last 60 days is 15,228 and the stock's 52-week low/high is $0.035/$0.105.

ActiveCare, Inc. (ACAR)

Beacon Equity Research, Stock Roach, InvestorSoup, TheLightningPicks, Stock Preacher, Penny Stocks Finder, StockHideout, Penny Stock Craze, PennyStockShark, Stock Professors, PennyStockRewards.com, and USA Market News reported earlier on ActiveCare, Inc.(ACAR), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Founded in 1998, ActiveCare, Inc. is a biotelematic technology company that lists on the OTC Markets: OTCQB. Based in Salt Lake City, Utah, the Company specializes in creating advanced products and services that help seniors manage and control their health and well-being while allowing them to remain active and independent while living in their own home. ActiveCare's business plan is to develop and market products for monitoring the health of and providing assistance to mobile and homebound seniors and the chronically ill. This includes those who may require a personal assistant to check on them during the day to ensure their safety and well-being.

Over the past decade or so, the Company has become the leader in location tracking technology. They were the first to combine an emergency cellular device with GPS tracking technology. ActiveCare's products and services are user-friendly; they provide personal care in helping seniors cope and overcome the many difficulties that arise as one ages. The Company markets their products through varied distribution channels. These include to self-insured employers, direct-to-consumer, medical device and equipment distributors, and health care providers and other caregivers.

Their technology incorporates cellular, GPS, as well as automatic fall detection in their hand-held and wearable Personal Assistance Link (PAL) device. The PAL connects members directly to the Company's 24/7 CareCenter and a CareSpecialist with the touch of a button. When a fall is detected, immediate service is provided. Through the CareCenter, they offer several concierge-like services to members.

By way of ActiveCare's CareCenter, members' medical data are stored including doctors, medications and care providers. Additionally, via their telematic technologies, they constantly know where the member is located in case of an emergency.

On March 8, 2012, ActiveCare acquired 4G Biometrics, LLC; a Texas limited liability company (4G). With the acquisition agreement, they acquired 100 percent of the member interests of 4G and 4G will be operated as a wholly owned subsidiary of ActiveCare. With the acquisition of 4G, ActiveCare expanded their fundamental business to include the monitoring of the well-being of the rapidly growing number of diabetics in the U.S.

ActiveCare, Inc. (ACAR), closed Tuesday's trading session at $0.07, up 67.71%, on 5,897 volume with 14 trades. The average volume for the last 60 days is 23,924 and the stock's 52-week low/high is $0.03/$0.50.

Loyalist Group Ltd. (LOY.V)

We are highlighting Loyalist Group Ltd.(LOY.V), here at the QualityStocks Daily Newsletter.

Loyalist Group Ltd. owns and operates private education schools in Toronto, Ontario and Vancouver, British Columbia. The Company offers English as a Second Language (ESL) Courses for international students; Training programs for teachers, commonly known as TESL; Professional Development Courses; and Corporate English for Professionals. Loyalist Group lists on the TSX Venture Exchange. The Company is based in Toronto, Ontario.

In October, Loyalist Group announced that they completed the acquisition of Cornerstone Academic College of ESL, Teacher Training and Test Preparation, Inc. (Cornerstone). The purchase price was $1.75 million.

In a press release dated October 22, 2012, Mr. Andrew Ryu, Chief Executive Officer of Loyalist Group, said, "Cornerstone is an important acquisition. It adds more than $4 million of profitable revenue to our top line and about 300 students, bringing our total enrolment to approximately 1,100. Increasing our student count is an important goal for two reasons: one is revenue, and the other is word-of-mouth marketing. We also expect to reap significant cost and revenue synergies at Cornerstone."

In addition, in October, Loyalist Group announced the execution of a definitive agreement for the acquisition of Victoria International Academy (VIA). The expectation is that the transaction will close on or about Nov. 9, 2012, subject to satisfaction of all conditions of closing and receipt of all required regulatory approvals. Loyalist Group will pay $355,000 for VIA. Of this total, $310,000 is payable in cash at the closing of the transaction. The balance of $45,000 is due four months after closing, subject to adjustment.

VIA is an English-as-a-Second-Language school. VIA has been operating in Victoria, British Columbia for the past 10 years. VIA enrolment stands at approximately 50 students - excluding online students.

The school earned revenues of approximately $600,000 in the fiscal year ended March 31, 2012. VIA is in good standing and compliant with Languages Canada and TESL Canada. The school has transfer agreements with Saanich School District, University of Victoria, Excel Career College, and Pacific Film and New Media Academy.

Loyalist Group Ltd. (LOY.V), closed Tuesday's trading at $0.59, up 1.72%, on 244,353 volume. The stock's 52-week low/high is $0.21/$0.65.

University General Health System, Inc. (UGHS)

Greenbackers and SmallCapVoice reported earlier on University General Health System, Inc. (UGHS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, University General Health System, Inc. is a diversified, integrated multi-specialty health care provider. The Company delivers concierge physician and patient-oriented services.
Currently, they operate one hospital, two ambulatory surgical centers, several diagnostic imaging and physical therapy clinics, and two hyperbaric wound care centers in the Houston area. University General has their headquarters in Houston, Texas.

The Company also owns three senior living facilities and manages six senior living facilities. In addition, University General owns a Support Services company that provides revenue cycle and luxury facilities management services.

The Company's current business was founded in 2005 to establish University General Hospital in Houston, Texas (UGH), a 69-bed physician-owned general acute care hospital. UGH provides inpatient, outpatient and ancillary services. These include inpatient surgery, outpatient surgery, heart catheterization procedures, physical therapy, diagnostic imaging and respiratory therapy. UGH provides 24-7 emergency services and comprehensive inpatient services including critical care and cardiovascular services.

University General's business model anticipates the acquisition of acute care "host" hospitals and the development and operation of regional health networks within a defined radius of each host hospital that can provide services under University General's acute care licenses. These regional health networks and ancillary services will reflect a vertically integrated, diversified system that will include provider-based "Hospital Outpatient Departments" (HOPDs) of the host hospitals and may consist of Ambulatory Surgical Centers, Free-Standing Emergency Rooms, Free-Standing Procedure Facilities, Diagnostic Imaging Treatment Facilities, HBOT/Wound Care Centers, and/or other ancillary service providers.

As of December 31, 2011, University General conducted operations via their wholly-owned subsidiaries, UGHS Hospitals, Inc., UGHS Ancillary Services, Inc., UGHS Management Services, Inc., UGHS Real Estate, Inc., UGHS Senior Living of Pearland, LLC, UGHS Senior Living of Port Lavaca, LLC, UGHS Senior Living of Knoxville, LLC, UGHS Autimis Billing, Inc., UGHS Coding, Inc., and Sybaris Group, Inc.

In early October 2012, University General Health System announced that they entered into a $19 million Financing Agreement with MidCap Financial, LLC. The agreement allowed the Company to refinance certain existing debt, while eliminating certain tax liabilities and other bank debt. The structure of the MidCap Agreement includes a line of credit for $15 million, which can be increased to $25 million under certain circumstances, and a $4 million term note.

University General Health System, Inc. (UGHS), closed Tuesday's trading session at $0.44, even with yesterday's close. The average volume for the last 60 days is 64,548 and the stock's 52-week low/high is $0.18/$0.47.

graphic

The QualityStocks
Company Corner

graphic
graphic

Cardium Therapeutics, Inc. (CXM)

The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.1905, up 0.26%, on 248,625 volume with 60 trades. The stock’s average daily volume over the past 60 days is 258,479, and its 52-week low/high is $0.1771/$0.47.

Cardium Therapeutics, Inc. today reported that the European Commission was the first major health regulatory authority to approve a gene therapy. The EU approval of uniQure's Glybera® (alipogene tiparvovec) represents a huge milestone for the gene therapy industry. This marketing authorization will make Glybera available to sufferers from severe and/or multiple pancreatitis attacks throughout all 27 EU member states, giving uniQure a strong in for U.S. and Canadian market approval (something they plan to pursue). Chairman and CEO of CXM, Christopher J. Reinhard, noted how this was an important step for a field where products like CXM's late-stage gene therapy Generx product candidate will likely see increasing uptake.

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer

Cardium Therapeutics, Inc. Company Blog

Cardium Therapeutics, Inc. News:

European Union's First Gene Therapy Approval Represents Major Advancement For Industry

DUMA - Duma Energy Corp, Zacks Initiating Coverage

Duma Energy Corp. Partners with Hydrocarb to Explore for World Class Reserves in Africa Oil Concession

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.24, even with yesterday's close, on 21,100 volume with 9 trades. The stock’s average daily volume over the past 60 days is 107,345, and its 52-week low/high is $0.21/$0.69.

International Stem Cell Corp. announced today that the company will have Executive VP, Dr. Simon Craw and CFO, Ms. Linh Nguyen host their upcoming Q3 2012 Financial Results Conference Call at 11:00 a.m. ET this Friday, November 9, 2012. Interested parties may attend at 1-877-317-6776 (U.S.), or 1-412-317-6776 (International) using Conference ID Number 10020806 and are encouraged to call in 10-minutes in advance of the start. The webcast at (http://webcast.mzvaluemonitor.com/Home/Login/630) will broadcast and a playback will be made available until November 26, 9:00 a.m. ET at 1-877-344-7529 (U.S.), or 1-412-317-0088 (International) using pin number 10020806.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation to Host Third Quarter 2012 Financial Results Conference Call at 11:00 a.m. ET on Friday, November 9, 2012

International Stem Cell Corp's Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs

International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine

Skinny Nutritional Corp. (SKNY)

The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.0019, up 5.56%, on 3,610,500 volume with 19 trades. The stock’s average daily volume over the past 60 days is 1,190,461, and its 52-week low/high is $0.0017/$0.0305.

Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.

The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.

The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.

Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer

Skinny Nutritional Corp. Blog

Skinny Nutritional Corp. News:

Skinny Nutritional Corp. Provides Update on Discussions With Trim Capital

Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+

A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $5.15, up 2.18%, on 41,921 volume with 25 trades. The stock’s average daily volume over the past 60 days is 42,621, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer

TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital

Cardium Therapeutics, Inc. (CXM) Reports European Union’s First Gene Therapy Approval

Today, Cardium Therapeutics announced the EU approval of uniQure’s Glybera® (alipogene tiparvovec). This first gene therapy approval by a major health regulatory authority represents a significant milestone and validation for the gene therapy industry.

Glybera® was developed to treat patients diagnosed with an inherited metabolic disease called familial lipoprotein lipase deficiency (LPLD or familial hyperchylomicronemia). The European Commission’s marketing authorization of Glybera covers all 27 European member states. uniQure plans to apply for regulatory approval in the U.S., Canada, and other countries.

“The EU approval of Glybera represents a major milestone for the global gene therapy industry,” commented Christopher J. Reinhard, Chairman and CEO of Cardium. “This is an important step forward for our field and the millions of patients expected to benefit from new and innovative gene-based therapeutics. Gene therapy offers the opportunity to simplify treatments for serious medical problems and to develop new products for which there are no current medical treatments.”

Cardium’s late-stage gene therapy Generx product candidate (Ad5FGF-4) is a disease-modifying interventional cardiology biologic being developed as a one-time non-surgical treatment for patients with coronary artery disease. Generx can be delivered using a standard cardiac catheter and is capable of promoting and enhancing cardiac perfusion in the heart through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis).

To learn more about Cardium and Generx, visit www.cardiumthx.com

International Stem Cell Corp. (ISCO) to Host Conference Call to Discuss Q3 2012 Financial Results

Earlier this morning, International Stem Cell Corp. announced that it will be hosting a conference call later this week. Dr. Simon Craw, Executive Vice President of International Stem Cell, and Ms. Linh Nguyen, Chief Financial Officer, will be present to discuss ISCO’s financial results for the three months ended September 30, 2012.

Those who wish to attend the call should note the information below:

Date: Friday, November 9, 2012
Time: 11:00 a.m. Eastern Time
Conference Line (U.S.): 1-877-317-6776
International Dial-In: 1-412-317-6776
Conference ID: 10020806
Webcast: http://webcast.mzvaluemonitor.com/Home/Login/630

Investors are advised to dial in at least 10 minutes before the call. Those unable to attend at the scheduled time will be able to listen to the recording by dialing 1-877-344-7529 within the United States or 1-412-317-0088 when calling internationally. Please use the replay pin number 10020806.

ISCO specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

For more information, visit www.internationalstemcell.com

GlobalWise Investments, Inc. (GWIV) Benefits from Intellinetics Technology

For more than two decades, GlobalWise wholly owned subsidiary Intellinetics has focused on helping organizations operate faster, leaner, and smarter by digging their way out of information. The company’s Enterprise Content Management (ECM) software, deployed via the cloud or stand-alone, is designed to facilitate the storage and access of documents and records, allowing them to flow freely with authorized 24/7 worldwide access. It’s a highly marketable product at a time when up to 85 percent of content, which can be critical to security and compliance issues, is essentially trapped as unstructured data.

Intellinetics’ software product architecture is Open Database Compliant (ODBC) and compatible with all major operating systems, offering seamless integration into virtually any existing database environment. Having the look and functionality of MS Windows, Intellinetics software is easy to deploy and use. The software utilizes an innovative mass-storage algorithm to compress stored information, so that files matching search specifications can be instantly retrieved, regardless of the number of files, the size of the network, or the number of simultaneous users.

Intellinetics’ flagship product, Intellivue, is an advanced document management platform, DMS-independent, representing an industry benchmark in compatibility, flexibility, and operational efficiency. It features DirectVU, easily linking with existing host business applications and sophisticated document imaging technology for distributed capture, automated indexing, advanced content extraction, and image cleanup.

Intellinetics also offers Redactivue, an advanced automated document redaction solution with accuracy, flexibility, and power. Redactivue is designed to enable users to quickly and efficiently design, test, and deploy intelligent redaction templates which support an unlimited number of unique content filters. Redactivue also includes a comprehensive quality review and approval workflow engine that is completely configurable by document category. As a result, unique law and policy requirements may be accommodated within one simple framework.

For additional information on GlobalWise Investments, visitwww.GlobalWiseInvestments.com

IGI Laboratories, Inc. (IG) to Launch First IGI Labeled Generic Topical Prescription Drug Products

Yesterday, New Jersey-based topical generic pharmaceutical company IGI Laboratories announced it will launch its first IGI labeled generic products later this year.

The company has an extensive partnership with Medimetriks Pharmaceuticals, Inc., which is a branded specialty pharmaceutical company focused on the dermatology market. As part of this relationship, IGI serves as Medimetriks’ authorized generic dealer for certain products. On Nov. 1, IGI received authorization to launch generic distribution of certain of Medimetriks’ recently launched Synalar (fluocinolone acetonide) line of prescription topical products.

IGI will work closely with Medimetriks to help ensure the successful launch of these generic topical prescription products. IGI believes this launch with its important partner is an essential component of the company’s long-term strategy. The current market conditions indicate a total addressable market for the first three products of around $30 million, of which IGI expects to achieve a meaningful market share.

Launch activity has commenced, and with the authorization to go to market, only a few steps remain before the company’s first IGI labeled generic topical product is ready to launch. The company has made significant strides in finalizing the needful state licensing requirements for commercial distribution. IGI is actively negotiating its logistics agreements with the proper wholesalers and retailers, and the company additionally plans to announce its distribution partner in the near future.

The pivot discussed in IGI’s last earnings call is well underway. With this launch, the company is in motion to deliver on its promise to become a leader in the generic topical pharmaceutical market.

IGI Laboratories is engaged in the development and manufacturing of topical formulations for the pharmaceutical, OTC, and cosmetic markets. The company’s aim is to become a leading player in the generic topical prescription drug market.

For more information, visit www.igilabs.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

OTCPicks
(COWI)

2.

SmallCapVoice
(PSID)

3.

Center Stage Stocks
(TGWI)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251